Coverage
-
April 11, 2013
AstraZeneca Pharmaceuticals LP settled its New Jersey patent infringement suit against Lupin Ltd. on Thursday, striking a deal in which Lupin agreed not to make or sell a generic version of AstraZeneca's extended-release schizophrenia drug Seroquel XR before November 2016.
1 other articles on this case.
View all »